Amphastar Director Sells 16,679 Shares for $441,800

Company Overview - Amphastar Pharmaceuticals, Inc. is a mid-cap biopharmaceutical company that specializes in specialty and generic injectable and inhalation products, leveraging a vertically integrated model with in-house API production and a diverse product pipeline to meet critical needs in acute care and emergency medicine [1][10] - The company focuses on both proprietary and generic products, positioning itself to capture demand from institutional healthcare providers and adapt to evolving market opportunities [1] Financial Performance - The company's stock was priced at approximately $26.49 per share during a recent transaction, closing at $26.37 on November 13, 2025, with a 42% decline over the prior 12 months [2][6] - Despite the annual decline, the stock has seen a 5% increase over the last month as of December 23, following FDA approval of its abbreviated New Drug Application for a teriparatide injection prefilled pen, used to treat severe osteoporosis [6] Insider Transactions - Floyd Petersen, a director at Amphastar Pharmaceuticals, sold 16,679 shares on November 13, 2025, after exercising stock options, resulting in a transaction valued at approximately $441,800 [4][5] - This sale was significantly larger than Petersen's historical median sell-only transaction of 500 shares, indicating a notable increase in activity [4] Share Buyback Program - Amphastar has a long-standing share-repurchase program, having bought back over 14.1 million shares for about $369.1 million since 2016, which is often viewed positively by investors as a sign of the company's belief in its stock's undervaluation [7]